Academics
follow us
  • Linkedin
  • Twitter
  • Facebook
  • Youtube
  • Instagram
Feedback
Patent Number:- IN448419

Benzamide Based HDAC3 Selective Inhibitors

  • Sector: Pharmaceutical Technology,
  • IPC: A61K, C07D,
 

Need

This invention aims to provide chemical compounds and pharmaceutical compositions for selective inhibition of histone deacetylase (HDAC) enzymes

Solution

The invention provides compounds and pharmaceutical compositions, including those selectively inhibiting HDAC enzymes.

Innovation

The invention introduces compounds and pharmaceutical compositions with specific structures targeting HDAC enzymes, potentially advancing treatments for various diseases and disorders.

Market Analysis

Market: Healthcare/Pharmaceutical Industry

CAGR: approximately 6-7%.

Potential Indian Clients: Pharmaceutical companies involved in drug discovery and development, such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Cadila Healthcare Ltd., and Biocon Ltd.

Why Invest?


Selective inhibitors

Epigenetic modifications

Genetic expression

Cancer treatment

At a Glance


Current TRL: NA

Funded by: NA

IPC: A61K, C07D

Domain: Pharmaceuticals/Drug Discovery

For more information, reach out to Mr. Rajneesh Kumar, Head of the Technology Transfer Office, at tto@bits-pilani.ac.in and 01596-255515.